Eliminating HCV Infection Among PWUD
Recruiting
- Conditions
- Hepatitis C, ChronicDrug Use
- Registration Number
- NCT05474781
- Lead Sponsor
- Vancouver Infectious Diseases Centre
- Brief Summary
Identify 300 PWUD with chronic, viremic HCV infection and engage them in a multidisciplinary, generalizable model of care and initiate HCV treatment
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
- Ability to review, sign and date the IRB/IEC approved informed consent form
- Age ≥19 years
- Documented HCV RNA positive for 6 months or more, with any HCV genotype
- Active PWUD (ongoing drug use or documented use within the previous 6 months) OR active enrolment in an opiate substitution program
Exclusion Criteria
- Previous DAA-based HCV treatment
- Pregnant or breast-feeding
- Indications of decompensated liver disease
- Diagnosis of active hepatocellular carcinoma
- Positive test at the time of screening for hepatitis B surface antigen (HBsAg)
- Frequent injecting drug use that is judged by the treating physician to compromise subsequent HCV treatment safety
- Inability or unwillingness to provide informed consent or to actively engage in care leading to the initiation of HCV treatment
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The proportion of individuals enrolled in the study who initiate HCV treatment 60 months
- Secondary Outcome Measures
Name Time Method The proportion of individuals enrolled in the study who achieve sustained virologic response 72 months
Trial Locations
- Locations (1)
Vancouver Infectious Diseases Centre
🇨🇦Vancouver, British Columbia, Canada